- <![CDATA[Institutional Perspectives on Treatment Thresholds in PLGG]]><![CDATA[Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.]]>onclive · 2mo ago↗ source
- <![CDATA[Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups]]><![CDATA[In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across diffe…onclive · 2mo ago↗ source
- <![CDATA[Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer]]><![CDATA[The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.]]>